The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ

IXCHIQ alphaviruses antibody breadth chikungunya virus (CHIKV) cross-neutralization infection vaccine

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
07 Aug 2024
Historique:
received: 06 07 2024
revised: 21 07 2024
accepted: 29 07 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: epublish

Résumé

The first vaccine against chikungunya virus (CHIKV) was recently licensed in the U.S., Europe, and Canada (brand IXCHIQ

Identifiants

pubmed: 39204019
pii: vaccines12080893
doi: 10.3390/vaccines12080893
pmc: PMC11359099
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NIAID NIH HHS
ID : R21 AI135537
Pays : United States
Organisme : NIH HHS
ID : AI135537
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI153434
Pays : United States
Organisme : NIH HHS
ID : AI153434
Pays : United States
Organisme : Valneva
ID : Sponsored research agreement (DNS)

Références

PLoS Negl Trop Dis. 2015 Apr 23;9(4):e0003684
pubmed: 25905779
PLoS Negl Trop Dis. 2023 Mar 13;17(3):e0011154
pubmed: 36913428
Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27637-27645
pubmed: 33087569
J Virol. 2014 Mar;88(5):2858-66
pubmed: 24371047
Cell. 2015 Nov 19;163(5):1095-1107
pubmed: 26553503
PLoS Pathog. 2007 Dec;3(12):e201
pubmed: 18069894
JCI Insight. 2022 Jul 22;7(14):
pubmed: 35700051
Int J Infect Dis. 2020 Jun;95:167-173
pubmed: 32247051
PLoS Pathog. 2019 Nov 7;15(11):e1008061
pubmed: 31697791
Proc Natl Acad Sci U S A. 2021 Sep 14;118(37):
pubmed: 34507983
Vaccines (Basel). 2020 May 05;8(2):
pubmed: 32380760
Vaccine. 2019 Nov 28;37(50):7427-7436
pubmed: 30448337
BMC Res Notes. 2022 Aug 3;15(1):271
pubmed: 35922804
J Virol. 2014 Nov;88(22):13333-43
pubmed: 25210177
Am J Trop Med Hyg. 2019 Jun;100(6):1541-1544
pubmed: 31017081
Epidemiol Infect. 2016 Jul;144(9):1912-6
pubmed: 26751121
Lancet Infect Dis. 2020 Oct;20(10):1193-1203
pubmed: 32497524
Am J Trop Med Hyg. 2000 Jun;62(6):681-5
pubmed: 11304054
PLoS Negl Trop Dis. 2014 Jul 24;8(7):e2970
pubmed: 25058320
Sci Transl Med. 2023 May 17;15(696):eade8273
pubmed: 37196061
Science. 2004 Jul 16;305(5682):371-6
pubmed: 15218094
Viruses. 2022 Oct 21;14(10):
pubmed: 36298867
Cell. 2021 Aug 19;184(17):4414-4429.e19
pubmed: 34416146
Lancet. 2023 Jun 24;401(10394):2138-2147
pubmed: 37321235
JCI Insight. 2017 Mar 23;2(6):e83527
pubmed: 28352649
BMC Infect Dis. 2018 Jan 30;18(1):61
pubmed: 29382300
Front Immunol. 2019 Oct 31;10:2563
pubmed: 31736977
Cell Host Microbe. 2020 Nov 11;28(5):699-711.e7
pubmed: 32783883
J Exp Med. 2019 Oct 7;216(10):2282-2301
pubmed: 31337735
PLoS Negl Trop Dis. 2015 May 07;9(5):e0003764
pubmed: 25951202
J Infect Dis. 2016 Dec 15;214(suppl 5):S475-S481
pubmed: 27920177
J Gen Virol. 2024 Feb;105(2):
pubmed: 38421278
Viruses. 2023 Jul 20;15(7):
pubmed: 37515274
Viruses. 2023 Jan 30;15(2):
pubmed: 36851608
PLoS Negl Trop Dis. 2016 Aug 29;10(8):e0004960
pubmed: 27571254
PLoS Pathog. 2022 Jul 5;18(7):e1010695
pubmed: 35788221
Viruses. 2024 Feb 29;16(3):
pubmed: 38543750
J Travel Med. 2024 Mar 1;31(2):
pubmed: 38091981
Lancet Reg Health Am. 2024 Jan 08;30:100673
pubmed: 38283942
Blood. 2014 Jun 5;123(23):3679-81
pubmed: 24904107
Emerg Microbes Infect. 2018 Feb 7;7(1):13
pubmed: 29410416
Science. 2015 Sep 18;349(6254):1338-43
pubmed: 26383952
J Infect Dis. 2020 Apr 27;221(10):1713-1723
pubmed: 31828322
Vaccines (Basel). 2022 Aug 23;10(9):
pubmed: 36146452
J Med Virol. 2012 Mar;84(3):462-70
pubmed: 22246833

Auteurs

Whitney C Weber (WC)

Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239, USA.

Zachary J Streblow (ZJ)

Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.

Craig N Kreklywich (CN)

Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.

Michael Denton (M)

Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.

Gauthami Sulgey (G)

Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.

Magdalene M Streblow (MM)

Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.

Dorca Marcano (D)

Ponce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico.

Paola N Flores (PN)

Ponce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico.

Rachel M Rodriguez-Santiago (RM)

Ponce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico.

Luisa I Alvarado (LI)

Ponce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico.

Vanessa Rivera-Amill (V)

Ponce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico.

William B Messer (WB)

Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239, USA.

Romana Hochreiter (R)

Valneva Austria GmbH, 1030 Vienna, Austria.

Karin Kosulin (K)

Valneva Austria GmbH, 1030 Vienna, Austria.

Katrin Dubischar (K)

Valneva Austria GmbH, 1030 Vienna, Austria.

Vera Buerger (V)

Valneva Austria GmbH, 1030 Vienna, Austria.

Daniel N Streblow (DN)

Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Division of Pathobiology and Immunology, Oregon National Primate Research Center, Beaverton, OR 97006, USA.

Classifications MeSH